Where the Fentanyl Crisis Really Starts: Inside the Chemical Networks Behind Synthetic Opioids

Fentanyl is frequently called the border crisis between the United States and Mexico, but the forces keeping it alive come from much earlier in the production chain. Synthetic opioids are made through chemical reactions that require precursors, which are then sold across the border areas in legitimate commercial networks. The scale of the crisis reflects the durability of those upstream supply structures rather than episodic trafficking events.

Illustration by The Geostrata

In 2024, there were around 79, 000 drug overdose deaths in the United States, with synthetic opioids, mainly illicitly manufactured fentanyl, causing the majority of opioid related deaths. The provisional data for the 12 months ending around mid 2025 estimate the number of overdose deaths at about 73, 000. These numbers point to a production system that continues to operate at a significant scale.

The patterns of enforcement serve to cement that reality. US Customs and Border Protection revealed that in the fiscal year 2023, they confiscated over 27, 000 pounds of fentanyl and huge quantities are still being intercepted through 2024 and into fiscal 2025. The quantities involved point to a continuous supply.

Over the past several years, the geography of precursor sourcing has changed quite a bit as the regulatory pressure of certain segments of the global market intensified. Supply networks did not vanish; they rather changed. Parts of the Indian chemical export sector have been found, through probes and arrests, to be linked with the upstream ecosystem, which had not been the case previously. Such a move was not a result of state policy in Delhi. It is the way globalised production works structurally, where activities move to less controlled areas when different jurisdictions are unevenly tightening oversight.

The question, then, is not simply where fentanyl is seized, but how effectively upstream chemical markets are governed in an interconnected global economy.

CHINA'S 2019 FENTANYL BAN

China took a significant step in April 2019 when it implemented class-wide scheduling of all fentanyl related substances. This method essentially meant that every analogue was controlled; thus, the government did not have to regulate individual compounds separately. After the move, which was part of bilateral counternarcotics discussions with the United States, the country extended restrictions to substances structurally similar to fentanyl, unless they were authorised for medical or research use.

Earlier, US authorities had traced the major supplies of finished fentanyl and key precursors such as ANPP and NPP to Chinese suppliers. The finished product was shipped directly to the United States, while the precursor chemicals moved through the commercial channels.

Following the controls, authorities reported a sharp decline in the sending of finished fentanyl from China. The illicit market did not disappear, however. Mexican trafficking organisations developed their domestic synthesis and, thus, they could rely less and less on the importation of finished products. Production was moved closer to the markets of distribution, while sourcing moved further upstream.

When ANPP and NPP were more tightly controlled, suppliers looked at pre precursor compounds such as 1-(tert-butoxycarbonyl)-4-piperidone, or N-BOC-4-Piperidone. These chemicals have genuine industrial applications, and their control was not uniform across regions. Regulation tends to target specific molecules, while synthetic chemistry operates across entire compound families. This gap allows substitution to move faster than scheduling.

Hence, the 2019 decision seems to have merely moved the scene of activity rather than thoroughly breaking it. The redirection of pressure on finished exports has made the earlier stages of the chemical supply more risky, where there is less supervision, and it is more difficult to determine the "intent" of the activities.

INDIA'S CHEMICAL ECONOMY

India's involvement in this supply chain is an indication of the makeup of its chemical economy. The country ranks as the third largest pharmaceutical manufacturer in the world by volume and annually exports pharmaceuticals worth over $27.8 billion. The chemicals sector in India, which is worth over 220 billion USD, is extensively involved in global trade of intermediates and is the supplier of inputs for regulated markets in North America and Europe. This magnitude explains the pivotal role of India in the world production of generic drugs.

What brings it up to date is the array, as production is spread out in the key industrial clusters of Gujarat, Maharashtra, and Telangana, where thousands of firms produce intermediates and active ingredients for export. The inputs often undergo several processing stages before they are finally sold.

In such a multilayered system, the supervision is dependent on the monitoring of the flow of products from one company to another and through different jurisdictions rather than checking a single producer situated at a centralised location.

The core of the issue is that many precursor and pre precursor compounds can be used for both legitimate and illicit purposes. Most of these chemicals used in the production of pharmaceuticals are legal. Their legality is determined by the declared end use, not by the chemical itself. Initially, the paperwork can prove that the export is legally compliant; however, a risk of diversion can occur at a later stage, invisible from the perspective of the exporting company. 

PRECURSOR DIVERSION CASES

Looking closely at each case, a key point stands out first. Proof does not show India guiding or pushing precursor shifts through official channels. Charges instead target particular businesses and people seen using weak spots in oversight. What stands out about these cases is how they were run, the way things moved, the size of it all laid out in court documents.

In January 2025, the US Department of Justice revealed a criminal charging Raxuter Chemicals and Athos Chemicals Pvt. Ltd., together with Bhavesh Lathiya a top executive, for conspiracy to distribute and import fentanyl precursor chemicals. The indictment states that the defendants allegedly supplied List I precursor chemicals to customers in the United States and Mexico, knowing they would be used in the manufacture of fentanyl.

According to the prosecutors, the companies resorted to deceptive measures in order to avoid detection, such as mislabeling shipments and forging customs papers. The indictment mentions a shipment that was declared as Vitamin C but was reportedly contained1-(tert-butoxycarbonyl)-4-piperidone  (N- BOC- 4- Piperidone), a chemical used in the production of fentanyl. Lathiya got detained in New York right after the indictment.

In March 2025, a separate indictment charged a Hyderabad-based company, Vasudha Pharma Chem Ltd and three executives, Tanweer Ahmed Mohamed Hussain Parkar, Venkata Naga Madhusudhan Raju Manthena and Krishna Vericharla, with several counts related to the illegal import and distribution of fentanyl precursor chemicals.

According to court records, the defendants allegedly sold 25 kilograms of N-BOC-4- Piperidone to an undercover agent in March 2024 and remitted another 25 kilograms in August 2024. The indictment also charges that the defendants were negotiating a four metric ton (4, 000 kilogram) purchase of the same precursor chemical, planned for shipment to Mexico. Parkar and Manthena were arrested in New York after the charges were unsealed.

Back in 2018, another major shipment of Mumbai showed the indication of the smuggling of chemicals even before the recent charges had surfaced. Almost 100 kilograms of NPP were hidden in shipping containers that were to be shipped abroad. The Anti-Narcotics Cell of Mumbai confiscated the load. That seizure exposed how difficult it is to control the chemicals that are able to have both legal and illegal uses.

CONCLUSION

The supply chain for fentanyl has a basic split: the same chemicals used to make legal medicines can also be taken and used to make illegal opioids. Their legality depends on the declared end use instead of the chemical identity, so illegal production doesn’t happen outside global trade but actually moves right through it. In that way, the system stays hidden not just because it's secret, but because it seems normal.

Concealment works according to the rules of commerce as shipments get mislabeled as low-risk items, sent through middlemen, or broken down into smaller packages. This way, they attract less attention but still keep the overall volume. Indictments involving Raxuter Chemicals and Vasudha Pharma Chem Ltd show how fake documents and misleading labels were used, proving that diversion can happen right through official export channels instead of being smuggled outside of them.

That's why policy needs to change earlier on. Instead of controlling molecules individually, authorities could put rules in place that limit substitutions across entire precursor families. Having harmonized control lists among the main exporting countries would help close regulatory gaps. Also, requiring end user certification along with checks after shipment would cut down the chances for diversion. Customs databases that work together with anomaly detection tools can help spot unusual trade activity early on, before it builds up.

The challenge is therefore structural: governance must evolve alongside the dual-use nature of modern chemical trade.

---

BY GUNJAN

TEAM GEOSTRATA

info@thegeostrata.com